Author's response to reviews

Title: Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Authors:

Maria Teresa Solomon (maisol@infomed.sld.cu)
Julio César Selva (selva@hcgqo.hlg.sld.cu)
Javier Figueredo (javierfm@infomed.sld.cu)
José Vaquer (jose.vaquer@infomed.sld.cu)
Carolina Toledo (carolina.toledo@infomed.sld.cu)
Nelson Quintanal (nelson.quintanal@infomed.sld.cu)
Silvia Salva (aperez@infomed.sld.cu)
Rafael Dominguez (rafael.dominguez@infomed.sld.cu)
José Alert (jalert@infomed.sld.cu)
Jorge Juan Marinello (soconcol@infomed.sld.cu)
Mauricio Catalá (mauricio.catala@infomed.sld.cu)
Martha Gonzalez Griego (martha.griego@infomed.sld.cu)
Juan Antonio Martell (juanantonio@cencec.sld.cu)
Patricia Lorenzo Luaces (patrcial@cim.sld.cu)
Javier Ballesteros (javier.ballesteros@ehv.es)
Niurys De Castro (niurys@ifal.uh.edu.cu)
Ferdinand Bach (fbach@oncoscience-ag.de)
Tania Crombet (taniac@cim.sld.cu)

Version: 5 Date: 2 May 2013

Author's response to reviews: see over
Answers to reviewers

Dear editor:

Thanks once more for the revision and the important comment provided: Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration.

Accordingly, the following statement was added to the Material and methods:

The trial was performed in compliance with the Helsinki Declaration. The protocol was approved by the Institutional Review Boards of the 8 research sites as well as by the National Regulatory Authority: the State Centre for Drug Quality Control. All patients signed the informed consent form.